粪便生物标志物在有症状患者中检测结直肠癌和腺瘤的诊断准确性
研究前瞻性纳入799例因下消化道症状由初级保健转诊行紧急检查的患者,430例完成结肠检查并交回粪便样本。粪便免疫化学检测(FIT)单独或联合粪便钙卫蛋白(FCP)对结直肠癌的阴性预测值均为99%,灵敏度84%、特异度93%;FCP联合未提供额外诊断信息。
要点
- FIT单独或联合FCP对结直肠癌的阴性预测值均为99%,灵敏度84%、特异度93%。
- FIT对腺瘤的阴性预测值单独或联合均为94%,灵敏度69%、特异度56%。
- 左侧结肠病变的FIT值显著高于右侧(713 vs 94,P=0.0203)。
核心结论
- 不可检测的粪便免疫化学检测血红蛋白足以排除结直肠癌,左侧病变中FIT值更高。
- FCP联合FIT似乎不提供额外诊断信息。
- 需要进一步研究确定在初级保健中实施FIT的健康经济效益。
研究设计与样本
- 前瞻性招募799例因下消化道症状由初级保健转诊行紧急检查的患者,其中430例完成结肠检查并交回粪便样本,纳入最终统计分析。
- FIT使用HM-JACKarc分析仪(Kyowa Medex,东京,日本)检测,FCP使用EliA钙卫蛋白免疫分析(Thermo Fisher Scientific,沃尔瑟姆,美国)检测。
主要发现
- FIT单独或FIT与FCP联合检测结直肠癌的阴性预测值相似,均为99%,灵敏度84%、特异度93%。
- 左侧结肠病变的FIT测量值显著高于右侧(713 vs 94,P=0.0203)。
- FIT单独或FIT与FCP联合检测腺瘤的阴性预测值相似,均为94%,灵敏度69%、特异度56%。
局限性
- 需要进一步研究确定在初级保健中实施FIT的健康经济效益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The diagnosis of colorectal cancer (CRC) can be difficult as symptoms are variable with poor specificity. Thus, there is a quest for simple, non-invasive testing that can help streamline those with significant colonic pathology. AIM: To assess using faecal immunochemical test for haemoglobin (FIT) or faecal calprotectin (FCP) to detect CRC and adenoma in symptomatic patients referred from primary care. METHODS: A total of 799 referred for urgent lower gastrointestinal investigations were prospectively recruited. Of these, 430 completed colonic investigations and returned stool samples, and were included in the final statistical analysis. Faecal immunochemical test for haemoglobin was performed on HM-JACKarc analyser (Kyowa Medex, Tokyo, Japan), and FCP by the EliA Calprotectin immunoassay (Thermo Fisher Scientific, Waltham, United States). RESULTS: The negative predictive value (NPV) using FIT alone or both markers (FIT and FCP) in combination was similar at 99% for CRC, with a sensitivity and specificity of 84% and 93%, respectively. FIT measurements were significantly higher in left-sided colonic lesions compared with the right side; 713 vs. 94; P = 0.0203). For adenoma, the NPV using FIT alone, or both markers (FIT and FCP) in combination, was similar at 94% with a sensitivity and specificity of 69% and 56%, respectively. CONCLUSIONS: Undetectable faecal immunochemical test for haemoglobin is sufficiently sensitive to exclude colorectal cancer, with higher values in left-sided lesions. FCP in combination does not appear to provide additional diagnostic information. Further studies to determine the health economic benefits of implementing faecal immunochemical test for haemoglobin in primary care are required.
引用
- Widlak MM, Thomas CL, Thomas MG, et al. Diagnostic accuracy of faecal biomarkers in detecting colorectal cancer and adenoma in symptomatic patients. Aliment Pharmacol Ther. 2016. PMID: 27910113. doi:10.1111/apt.13865
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。